Objective To observe the clinical efficacy of ursodeoxycholic acid for recovering liver function in patients with drug-induced liver disease.Methods One-hundred-and-thirty patients with drug-induced liver disease were randomly assigned to a control treatment group (n=68) or an experimental treatment group (n=62) .The control group received the standard hepatinica therapy of diammonium glycyrrhizinate, reduced glutathione, and polyene phosphatidylcholine.The experimental group received ursodeoxycholic acid at 12-15 mg·kg-1·d-1 P.O.in three divided doses.The treatment course lasted for four weeks for both groups.Liver function was assessed by serum chemistry prior to treatment initiation, and two and four weeks after treatment completion.Results Liver function improved after treatment in both groups, but the ursodeoxycholic acid treatment group showed significantly more improvement than the standard treatment group (P<0.01) .Conclusion Ursodeoxycholic acid has beneficial therapeutic effect for resolving impaired liver function in drug-induced liver disease and may represent a superior treatment to the traditional hepatinica drugs.
[1]Benchiou C.Criteria of drug-induced liver disorders reportof an international consensus meeting[J].J Hepatol, 2000, 24 (8) :85.
|
[2]Fickert P, Zollner G, Fuchsbichler A, et al.Effects of ur-sodeoxycholic and cholic acid feeding on hepatocellular trans-porter expression in mouse liver[J].Gastroenterology, 2000, 12 (5) :511-515.
|
[3]Ulrich Beuers.Drug Insight:mechanisims and sites of actionof ursodeoxycholic acid in cholestasis[J].Nat Clini Prac Gas-troenterol Hepatol, 2005, 3 (2) :85-178.
|
[4] 姚福军, 牛小莉.药物性肝病的特点分析[J].中华传染病杂志, 2005, 12 (3) :161-362.
|
[1] | Xia SHENG, Qingming JI, Xinyu LI, Lihong WANG, Junqi NIU. Advances in drug therapy for primary sclerosing cholangitis[J]. Journal of Clinical Hepatology, 2024, 40(5): 1032-1038. doi: 10.12449/JCH240526 |
[2] | Nan WANG, Rong HU, Shihui BIAN, Wei ZHONG, Pengfei ZHANG, Youwen TAN. Value of alkaline phosphatase level after ursodeoxycholic acid treatment for one month and baseline red blood cell distribution width in predicting the treatment response of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2024, 40(3): 496-501. doi: 10.12449/JCH240310 |
[3] | Xinyu CUI, Yanyan LI, Na ZHU, Yingying LIN, Xin LI. Efficacy of ursodeoxycholic acid in the prevention and treatment of COVID-19 in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2024, 40(3): 489-495. doi: 10.12449/JCH240309 |
[4] | Zhang YuGuo, Zhao SuXian, Li WenCong, Ren WeiGuang, Nan YueMin. Clinical effect of ursodeoxycholic acid combined with diammonium glycyrrhizinate in treatment of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1322-1325. doi: 10.3969/j.issn.1001-5256.2019.06.028 |
[5] | Liu ChengHai, Zhu ChunWu. Epidemic features, major causes, and diagnostic evaluation of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2017, 33(5): 829-832. doi: 10.3969/j.issn.1001-5256.2017.05.007 |
[6] | Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2015, 31(11): 1752-1769. doi: 10.3969/j.issn.1001-5256.2015.11.002 |
[7] | Wang LiFeng, Li YuanYuan, Jin Lei, Wang FuSheng. Epidemiology and natural history of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 165-170. doi: 10.3969/j.issn.1001-5256.2015.02.005 |
[8] | Zhu JiangYi, Han Ying. Research advances in primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 163-164. doi: 10.3969/j.issn.1001-5256.2015.02.004 |
[9] | Qi YaBin, Qiu Ling, Jiang HongLi, Zhang Rui, Hu YuLin. Clinical characteristics of drug-induced liver injury: an analysis of 394 cases[J]. Journal of Clinical Hepatology, 2014, 30(5): 438-441. doi: 10.3969/j.issn.1001-5256.2014.05.014 |
[10] | Qin Hua, Bai ShiShan. Advances in treatment of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(9): 719-721. doi: 10.3969/j.issn.1001-5256.2013.09.023 |
[11] | Yu XiaoFang. Captopril-induced liver injury and considerations for hepatitis[J]. Journal of Clinical Hepatology, 2012, 28(7): 549-550. |
[12] | Su HaiBin, Wang HuiFen. Clinical significance of drug-induced liver failure[J]. Journal of Clinical Hepatology, 2012, 28(10): 738-739+747. |
[13] | Wang ChunYan, Li Bing. One case of congenital hepatic fibrosis and hepatitis B virus infection and drug-induced liver injury[J]. Journal of Clinical Hepatology, 2011, 27(12): 1318-1319. |
[14] | Zhu ChaoHui, Li Nan, Wu Kai, Wang XueMing, Zhang Lin, Zhai JunShan, Wang YanMei. The effect of S-adenosyl-methionine treatment on drug-induced liver injury[J]. Journal of Clinical Hepatology, 2010, 26(6): 651-653. |
[15] | Gao Feng, Zhang FuKui, Jia JiDong. Liver function changes of ursodeoxycholic acid made in china for patients with primary biliary cirrhosis.[J]. Journal of Clinical Hepatology, 2008, 24(4): 278-280. |
[16] | Qin Gang, Shi GuangFeng, Li Qian, Lu Qing, Chen Shu. Inhibitory effects of UDCA on porcine serum-induced rat liver fibrosis[J]. Journal of Clinical Hepatology, 2007, 23(4): 263-265. |
[17] | Tang ShuZhen, Liu XiaoMing, You Hong, Zhang FuKui, Wang BaoEn, Jia JiDong. Autoimmune related clinical tests in diagnosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2006, 22(3): 191-192. |
[19] | Tan YouWen, Wu JianCheng, Wu XueJun. Efficacy of ursodeoxycholic acid in the treatment of type Ⅰ autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2004, 20(5): 283-284. |